Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Immunity
|
May 26, 2022
Dendritic cells can prime anti-tumor CD8<sup>+</sup> T cell responses through major histocompatibility complex cross-dressing
Brendan W MacNabb, Sravya Tumuluru, Xiufen Chen, et al.
Blood
|
March 27, 2019
<i>PD-L1</i> gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
James Godfrey, Sravya Tumuluru, Riyue Bao, et al.
Blood Advances
|
August 16, 2022
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
James Godfrey, Hongtao Liu, Jovian Yu, et al.
Scientific Data
|
May 24, 2022
Machine-learning ready data on the thermal power consumption of the Mars Express Spacecraft
Matej Petković, Luke Lucas, Jurica Levatić, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2023
TIGIT is a key inhibitory checkpoint receptor in lymphoma
James Godfrey, Xiufen Chen, Nicole Sunseri, et al.
Leukemia & Lymphoma
|
August 6, 2025
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma
Annie Xiao, Lu Chen, Stacy Pak, et al.
Haematologica
|
January 12, 2023
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
Joo Y Song, Mary Nwangwu, Ting-Fang He, et al.
American Journal of Hematology
|
September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma
Shin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 12, 2019
Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities
Charles Van Slambrouck, Jooryung Huh, Cheolwon Suh, et al.
Hemasphere
|
May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma
Matthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Immunity
|
May 26, 2022
Dendritic cells can prime anti-tumor CD8<sup>+</sup> T cell responses through major histocompatibility complex cross-dressing
Brendan W MacNabb, Sravya Tumuluru, Xiufen Chen, et al.
Blood
|
March 27, 2019
<i>PD-L1</i> gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
James Godfrey, Sravya Tumuluru, Riyue Bao, et al.
Blood Advances
|
August 16, 2022
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
James Godfrey, Hongtao Liu, Jovian Yu, et al.
Scientific Data
|
May 24, 2022
Machine-learning ready data on the thermal power consumption of the Mars Express Spacecraft
Matej Petković, Luke Lucas, Jurica Levatić, et al.
Journal for Immunotherapy of Cancer
|
June 26, 2023
TIGIT is a key inhibitory checkpoint receptor in lymphoma
James Godfrey, Xiufen Chen, Nicole Sunseri, et al.
Leukemia & Lymphoma
|
August 6, 2025
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma
Annie Xiao, Lu Chen, Stacy Pak, et al.
Haematologica
|
January 12, 2023
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
Joo Y Song, Mary Nwangwu, Ting-Fang He, et al.
American Journal of Hematology
|
September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma
Shin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 12, 2019
Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities
Charles Van Slambrouck, Jooryung Huh, Cheolwon Suh, et al.
Hemasphere
|
May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma
Matthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Page
of 3